Esophageal cancer other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Esophageal cancer}} | {{Esophageal cancer}} | ||
{{CMG}}{{AE}}{{HM}} | {{CMG}}; {{AE}}{{HM}} | ||
==Overview== | ==Overview== | ||
Other imaging studies for esophageal cancer include | Other imaging studies for esophageal cancer include [[positron emission tomography]] scanning with 18-fluorodeoxyglucose ([[FDG-PET]]). [[FDG-PET]] is a noninvasive staging modality that is more sensitive than [[Computed tomography|CT]] or [[Endoscopic ultrasound|EUS]] for the detection of distant metastases. | ||
==Other Imaging Studies== | ==Other Imaging Studies== | ||
=== FDG-PET === | === FDG-PET === | ||
* FDG-PET is a noninvasive staging modality that is more sensitive than [[Computed tomography|CT]] or [[Endoscopic ultrasound|EUS]] for the detection of distant metastases.<ref name="pmid18212745">{{cite journal |vauthors=van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD |title=Staging investigations for oesophageal cancer: a meta-analysis |journal=Br. J. Cancer |volume=98 |issue=3 |pages=547–57 |year=2008 |pmid=18212745 |pmc=2243147 |doi=10.1038/sj.bjc.6604200 |url=}}</ref><ref name="pmid10986052">{{cite journal |vauthors=Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L |title=Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma |journal=J. Clin. Oncol. |volume=18 |issue=18 |pages=3202–10 |year=2000 |pmid=10986052 |doi=10.1200/JCO.2000.18.18.3202 |url=}}</ref><ref name="pmid9016218">{{cite journal |vauthors=Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD |title=Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography |journal=AJR Am J Roentgenol |volume=168 |issue=2 |pages=417–24 |year=1997 |pmid=9016218 |doi=10.2214/ajr.168.2.9016218 |url=}}</ref> | * [[FDG-PET]] is a noninvasive staging modality that is more sensitive than [[Computed tomography|CT]] or [[Endoscopic ultrasound|EUS]] for the detection of distant metastases.<ref name="pmid18212745">{{cite journal |vauthors=van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD |title=Staging investigations for oesophageal cancer: a meta-analysis |journal=Br. J. Cancer |volume=98 |issue=3 |pages=547–57 |year=2008 |pmid=18212745 |pmc=2243147 |doi=10.1038/sj.bjc.6604200 |url=}}</ref><ref name="pmid10986052">{{cite journal |vauthors=Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L |title=Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma |journal=J. Clin. Oncol. |volume=18 |issue=18 |pages=3202–10 |year=2000 |pmid=10986052 |doi=10.1200/JCO.2000.18.18.3202 |url=}}</ref><ref name="pmid9016218">{{cite journal |vauthors=Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD |title=Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography |journal=AJR Am J Roentgenol |volume=168 |issue=2 |pages=417–24 |year=1997 |pmid=9016218 |doi=10.2214/ajr.168.2.9016218 |url=}}</ref> | ||
* In 20% of cases, management of esophageal cancer was changed after being scanned with FDG-PET.<ref name="pmid10986052">{{cite journal |vauthors=Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L |title=Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma |journal=J. Clin. Oncol. |volume=18 |issue=18 |pages=3202–10 |year=2000 |pmid=10986052 |doi=10.1200/JCO.2000.18.18.3202 |url=}}</ref> | * In 20% of cases, management of esophageal cancer was changed after being scanned with [[FDG-PET]].<ref name="pmid10986052">{{cite journal |vauthors=Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L |title=Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma |journal=J. Clin. Oncol. |volume=18 |issue=18 |pages=3202–10 |year=2000 |pmid=10986052 |doi=10.1200/JCO.2000.18.18.3202 |url=}}</ref> | ||
*FDG-PET siginificantly improves the detection of stage IV esophageal cancer. | *[[FDG-PET]] siginificantly improves the detection of stage IV esophageal cancer. | ||
==References== | ==References== | ||
Latest revision as of 16:37, 5 January 2018
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer other imaging findings On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer other imaging findings |
|
Risk calculators and risk factors for Esophageal cancer other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Other imaging studies for esophageal cancer include positron emission tomography scanning with 18-fluorodeoxyglucose (FDG-PET). FDG-PET is a noninvasive staging modality that is more sensitive than CT or EUS for the detection of distant metastases.
Other Imaging Studies
FDG-PET
- FDG-PET is a noninvasive staging modality that is more sensitive than CT or EUS for the detection of distant metastases.[1][2][3]
- In 20% of cases, management of esophageal cancer was changed after being scanned with FDG-PET.[2]
- FDG-PET siginificantly improves the detection of stage IV esophageal cancer.
References
- ↑ van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008). "Staging investigations for oesophageal cancer: a meta-analysis". Br. J. Cancer. 98 (3): 547–57. doi:10.1038/sj.bjc.6604200. PMC 2243147. PMID 18212745.
- ↑ 2.0 2.1 Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L (2000). "Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma". J. Clin. Oncol. 18 (18): 3202–10. doi:10.1200/JCO.2000.18.18.3202. PMID 10986052.
- ↑ Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD (1997). "Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography". AJR Am J Roentgenol. 168 (2): 417–24. doi:10.2214/ajr.168.2.9016218. PMID 9016218.